<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4">Mucoraceous moulds &amp; mucormycosis</h1><h3 class="text-lg font-semibold mt-6 mb-3"><strong>1. Taxonomy &amp; Key Species</strong></h3><p class="ml-4 mb-2">Two medically important orders: <strong>Mucorales</strong> and <strong>Entomophthorales</strong>; formerly grouped in polyphyletic <em>Zygomycota</em>.Common human-pathogenic genera (Box 18.1): <em>Rhizopus</em> (esp. <strong>R. arrhizus</strong>—most frequent), <em>Lichtheimia</em> (formerly <em>Absidia</em>), <em>Mucor</em>, <em>Rhizomucor</em>, <em>Cunninghamella</em>, <em>Saksenaea</em>, <em>Apophysomyces</em>; entomophthoromycosis agents <em>Basidiobolus ranarum</em> and <em>Conidiobolus coronatus</em> .</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>2. Biology &amp; Pathogenesis</strong></h3><p class="ml-4 mb-2">Broad, <strong>pauci-septate “ribbon-like” hyphae</strong> that branch at ~90° .Rapid growth at 37 °C; sporangiospores produced in sporangia; some genera form rhizoids for anchoring .<strong>Virulence mechanisms:</strong> fast angio-invasive growth causing vessel thrombosis/necrosis; high iron affinity (disease worse in iron overload or deferoxamine therapy) .Larger spore size favours entrapment in nasal turbinates ⇒ rhinocerebral disease more common than pulmonary .Many Mucorales form thick-walled <strong>zygospores</strong> (sexual stage) that survive extreme conditions — possible environmental reservoir</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>3. Epidemiology &amp; Risk Factors</strong></h3><table><tr><td><p><strong>Major host factors</strong></p></td><td><p><strong>Illustrative notes</strong></p></td></tr><tr><td><p><strong>Diabetes mellitus (DKA)</strong></p></td><td><p>Commonest risk </p></td></tr><tr><td><p><strong>Haematological / other malignancies &amp; neutropenia</strong></p></td><td><p>Second most frequent; post-allo-SCT incidence ≈0.3 %, 1-yr survival &lt; 25 % </p></td></tr><tr><td><p><strong>Trauma &amp; burns</strong></p></td><td><p>Includes natural disasters, tornadoes, floods, combat wounds </p></td></tr><tr><td><p><strong>Solid-organ transplant &amp; prolonged steroids (GVHD)</strong></p></td><td><p>Lung / heart-lung recipients particularly vulnerable </p></td></tr><tr><td><p><strong>Iron overload / deferoxamine</strong></p></td><td><p>Siderophore-mediated infection </p></td></tr><tr><td><p><strong>Nosocomial sources</strong></p></td><td><p>Contaminated linens, wooden tongue-depressors</p></td></tr></table><p>Overall European incidence ≈ 1 case / 10^6 population; likely rising.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>4. Clinical Syndromes</strong></h3><p class="ml-4 mb-2"><strong>Rhinocerebral</strong>: sinus pain, facial swelling, cranial nerve palsies, black palatal/nasal eschar .<strong>Pulmonary</strong>: nodular/segmental infiltrates mimicking invasive aspergillosis; “reversed halo” CT sign .<strong>Cutaneous / wound</strong>: necrotic eschar, rapidly extending cellulitis or fasciitis.<strong>Disseminated</strong>: any organ, often skin lesions secondary to pulmonary focus .<strong>Entomophthoromycosis</strong>:<em>Basidiobolus</em>: chronic subcutaneous masses (trunk/limb) or GI pseudotumour .<em>Conidiobolus</em>: painless mid-facial swelling (“woody” rhinofacial lesion) .</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>5. Diagnosis</strong></h3><p><strong>Immediate</strong></p><p class="ml-4 mb-2">Direct microscopy of tissue (KOH/Calcofluor): broad, ribbon-like hyphae with right-angle branching .Histology (Grocott): angio-invasion, necrosis.</p><p> <strong>Culture</strong></p><p class="ml-4 mb-2">Grow rapidly in ≤ 24 h on glucose-peptone agar at 30–37 °C; <strong>do not homogenise tissue</strong> (destroys hyphae) .Identify by sporangial morphology, rhizoids, thermotolerance; confirm with ITS/28S sequencing if sporulation poor .In histology: <strong>Splendore-Hoeppli phenomenon</strong> (eosinophilic cuffs around hyphae) can appear in entomophthoromycosis and is a useful histological clue.</p><p> <strong>Adjunct tests</strong></p><p class="ml-4 mb-2">Serum (1→3)-β-D-glucan <strong>negative</strong> (low cell-wall content) .Imaging: CT “reversed halo” in lungs .Experimental pan-fungal PCR on tissue / blood; useful when cultures negative .</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>6. Management</strong></h3><p class="ml-4 mb-2"><strong>Urgent combined therapySurgical debridement</strong> of necrotic tissue (often extensive) .<strong>First-line antifungal</strong>: lipid complex or liposomal <strong>Amphotericin B 5–10 mg kg⁻¹ d⁻¹</strong> (formulation-specific) .<strong>Azole step-down / salvagePosaconazole</strong> (delayed-release tablet or IV) OR<strong>Isavuconazole</strong>—licensed for primary or salvage therapy (open-label VITAL trial) .<strong>Adjuncts (case-by-case)</strong>Reversal of immunosuppression / DKA.Hyperbaric oxygen, iron chelation with deferasirox (not deferoxamine), G-CSF or GM-CSF, interferon-γ; <strong>evidence limited</strong> .Topical 0.1–0.25 % acetic acid for superficial disease (experimental) .<strong>Entomophthoromycosis</strong>: prolonged <strong>itraconazole</strong> ± saturated potassium iodide or cotrimoxazole; surgery rarely needed .<strong>Monitoring</strong>Therapeutic drug monitoring for posaconazole/isavuconazole.Serial imaging &amp; histology to guide further resection.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>7. Prognosis &amp; Prevention</strong></h3><p class="ml-4 mb-2">Mortality remains high (40–80 %) and correlates with delay to therapy, uncontrolled underlying disease, and disseminated spread .<strong>Infection-control</strong>: single-use dressings, HEPA filtration, proper linen laundering; avoid wooden devices in NICU .Hospital Outbreaks: Rising incidence noted since mid-2000s; contaminated <strong>hospital linen</strong> and <strong>wooden tongue-depressors</strong> caused recent outbreaks.<strong>Risk factors: Alcohol/IV-drug use, natural disasters (floods/tornadoes)</strong> and <strong>near-drowning injuries</strong> crop up in case literature<strong>Prophylaxis</strong>: posaconazole in selected high-risk haematology/SCT patients (institutional policy driven).</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>8. High-Yield Exam Pearls</strong></h3><p class="ml-4 mb-2"><em>Rhizopus arrhizus</em> = commonest agent; think of <strong>DKA patient with black nasal eschar</strong>.Negative β-D-glucan differentiates mucormycosis from Aspergillus/Candida.<strong>Reversed halo sign</strong> is characteristic but not pathognomonic.<strong>Do not homogenise</strong> surgical tissue—culture yield plummets.Liposomal AmB first; switch to isavuconazole/posaconazole only when clinically improving or nephrotoxicity limits therapy.</p>
</div>